Arrowhead Pharmaceuticals (ARWR) Expected to Announce Earnings on Tuesday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is expected to post its Q4 2025 results after the market closes on Tuesday, November 25th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.09) per share and revenue of $147.53 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 25, 2025 at 4:30 PM ET.

Arrowhead Pharmaceuticals Stock Down 2.7%

NASDAQ:ARWR opened at $40.15 on Tuesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. The firm has a market cap of $5.55 billion, a P/E ratio of -31.37 and a beta of 1.27. Arrowhead Pharmaceuticals has a fifty-two week low of $9.57 and a fifty-two week high of $43.69. The firm has a 50-day simple moving average of $36.11 and a two-hundred day simple moving average of $23.99.

Insider Activity

In other news, insider James C. Hamilton sold 20,000 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total value of $700,000.00. Following the completion of the sale, the insider directly owned 212,122 shares in the company, valued at $7,424,270. This represents a 8.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last ninety days, insiders have sold 50,000 shares of company stock worth $1,525,000. Insiders own 4.30% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ARWR. iSAM Funds UK Ltd bought a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $29,000. Daiwa Securities Group Inc. increased its stake in shares of Arrowhead Pharmaceuticals by 883.3% in the second quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 3,763 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $91,000. Quadrant Capital Group LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at $140,000. Finally, State of Wyoming bought a new position in Arrowhead Pharmaceuticals in the 2nd quarter worth $142,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Analyst Ratings Changes

ARWR has been the subject of a number of recent analyst reports. Morgan Stanley boosted their price objective on shares of Arrowhead Pharmaceuticals from $29.00 to $45.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. Chardan Capital reaffirmed a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, August 11th. TD Cowen upgraded Arrowhead Pharmaceuticals to a “strong-buy” rating in a report on Monday, July 28th. Finally, Royal Bank Of Canada decreased their target price on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating for the company in a research report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $43.38.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.